Beads (2)Antibody (11)
Launched (13)
Mouse (13)
- (7)Human IgG1 (5)Mouse IgG1 (1)
- (2)Unconjugated (5)HRP Labeled (1)Acridinium ester Labeled (1)PE Labeled (2)AF488 Labeled (1)Biotin-labeled (1)
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Praluzatamab ravtansine | CX-2009 | Phase 2 Clinical | Immunogen Inc, Cytomx Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |

[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email:order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
BettinastraBe 30, 60325 Frankfurt am Main




